Lycia Therapeutics LYCA

Venrock Healthcare Capital Partners III, L.P. (10% owner) bought 25,004 LYCA at $25.78, worth $645K

Form: 4
Filed: Oct 30, 2026, 7:25 pm ET
Importance: Major
Accession: 0001231919-26-001519

Purchased 10,570 shares at $25.23
Purchased 4,430 shares at $25.97
Purchased 8,804 shares at $26.27
Total owned shares now 6,850,237

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the app Get the app View on EDGAR

The reading, claim by claim

The filing includes details about transactions involving Lycia Therapeutics, Inc., with the earliest transaction date listed as October 28, 2026.
The form is required under Section 16(a) of the Securities Exchange Act of 1934.
The filing indicates that Venrock Healthcare Capital Partners III, L.P. is a reporting person with a connection to Lycia Therapeutics, Inc. The form includes information about the ownership structure and the nature of the securities involved.
It also notes whether the transaction was made under a contract, instruction, or written plan.
The filing specifies that Venrock Healthcare Capital Partners III, L.P. is based in New York, United States, and is associated with Lycia Therapeutics, Inc. The form includes details about the reporting person's address and the issuer's ticker symbol, LYCA.
It also outlines the relationship between the reporting person and the issuer.

6 of 7 claims matched the filing text.

Not found in the filing text

Venrock Healthcare Capital Partners III, L.P. filed a Form 4 on October 30, 2026, reporting changes in beneficial ownership of securities.

From the filing

Filing text

SEC Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934² or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).⁴ See Instruction 10.

1.³ ³Name and Address of Reporting Person * Venrock Healthcare Capital Partners III, L.P.³

(Last) (First) (Middle)⁵

C/O VENROCK 7 BRYANT PARK, 23RD FLOOR⁵

(Street) NEW YORK⁵

(City) (State) (Zip)⁵

UNITED STATES⁵

(Country)⁵ 2.¹ ¹Issuer Name and Ticker or Trading Symbol¹

Lycia Therapeutics, Inc.¹

[ LYCA ]

5.⁶ ⁶Relationship of Reporting Person(s) to Issuer⁶

(Check all applicable)⁶ Director X 10% Owner

Officer (give title below) Other (specify below)

2a. Foreign Trading Symbol

3.¹ ¹Date of Earliest Transaction¹

(Month/Day/Year)¹

10/28/2026¹ 6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

X Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed

(Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

3)

2. Transaction Date

(Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr.

8)

4. Securities Acquired (A) or Disposed Of (D) (Instr.

3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

7. Nature of Indirect Beneficial Ownership (Instr.

4)

Code V Amount (A) or (D) Price

Co

Similar companies

Same SIC code (2836) and public float not reported.